« Roslin Cells works with winning team to accelerate dementia drug discovery process | Main | Roslin Cells to manufacture blood cultured from stem cells »

Roslin Cells Announces New Cell Therapy Manufacturing Contract with Pfizer Inc.

Edinburgh, Scotland, 21st May 2014

Roslin Cells announced today that it has signed a contract with Pfizer Inc., acting through Neusentis, a research unit of Pfizer based in Cambridge, UK, to support the manufacture of retinal pigment epithelium (RPE) cells to be used in a cell therapy clinical trial.  This trial will evaluate the therapy for the treatment of patients suffering from age related macular degeneration (AMD), the major cause of loss of vision in people aged 65 and older, as part of an ongoing collaboration with The London Project at the Institute of Ophthalmology, UCL.

Janet Downie, Chief Operating Officer of Roslin Cells commented, “We are delighted to be supporting Pfizer in this exciting clinical trial which allows us to further develop our cell therapy contract manufacturing business in Edinburgh.”

Manufacturing will take place in the company’s GMP Cellular Therapy Manufacturing Facility in Edinburgh, which was licensed by the Medicines Healthcare Products Regulatory Agency (MHRA) in May 2013 for the manufacture of human cell therapy products for clinical trials.  Aidan Courtney, CEO of Roslin Cells, commented,“This contract builds on our success to secure other leading cell therapy programmes and demonstrates our position in regenerative medicine in Europe.  It represents the culmination of a four year programme to design, build and commission a premier facility for cell therapy development here in Edinburgh”.

About Roslin Cells

Roslin Cells is a leader in the development of cell therapies and provides Good Manufacturing Practice (GMP) manufacturing services for cell therapy products for clinical use.  Headquartered at the Edinburgh BioQuarter, the Company operates a state of‐the‐art, GMP Cellular Therapy manufacturing facility in partnership with the Scottish National Blood Transfusion Service (SNBTS). In addition to manufacturing established cellular products, Roslin Cells supports commercial and academic clients to develop new cell therapies by providing full process development and translational capabilities including early phase GMP manufacturing of cellular therapies for clinical trials. 

The Company is also a leader in the large scale production of stem cells for research and collaborates with researchers across Europe to accelerate the use of stem cells in life science research.


Press Contacts

For more information, please contact:

Roslin Cells

Janet Downie, Chief Operating Officer, Tel.  +44 (0)7500 766 181

Email: janet.downie@roslincells.com

Web : www.roslincells.com

PrintView Printer Friendly Version

EmailEmail Article to Friend